The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Uneasy alliance—clinical investigators and the pharmaceutical industry
Abstract
Clinical practice is changing rapidly. New cardiovascular drugs, antiinflammatory drugs, cancer chemotherapy, and other pharmacologic weapons are being added to physicians' therapeutic armamentarium virtually daily. Most clinical studies that bring new drugs from bench to bedside are financed by pharmaceutical companies. Many of these drug trials are rigorously designed, employing the skills of outstanding clinical researchers at leading academic institutions.But academic medical centers are no longer the sole citadels of clinical research. The past 10 years have seen the spectacular growth of a new research model. Commercially oriented networks of contract-research organizations (CROs) and site-management organizations (SMOs) have altered . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COVID-19 case surges may cause disruption over a wide spectrum of societal and healthcare system activities. 1,385 387”
From European Resuscitation Council Guidelines 2021: Ethics of resuscitation and end of life decisions (2021) · cites this paper as [387]
Citations
Cites
Conflict of Interest in the Debate over Calcium-Channel Antagonists
Stelfox, H. T., Chua, G., O'Rourke, K., & Detsky, A. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380206 · Cited by 615
Source of funding and outcome of clinical trials
Davidson, R. A. (1986) · Journal of General Internal Medicine · doi:10.1007/bf02602327 · Cited by 397
Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Johansen, H. K. (1999) · JAMA · doi:10.1001/jama.282.18.1752 · Cited by 128
Research works printed but not linked: 29
- Cho MK, 1996, Ann Intern Med, 124, 485, 10.7326/0003-4819-124-5-199603010-00004 · DOI
- 10.1001/jama.282.15.1453 · DOI
- Chow S-C, Liu J-P. Design and analysis of clinical trials. New York: John Wiley, 1998.
- 10.1001/jama.282.8.786 · DOI
- 10.1001/jama.282.20.1947 · DOI
- 1997, CenterWatch, 4, 1, 9
- Henderson L, 1999, CenterWatch, 6, 1, 4
- Vogel JR, 1999, Appl Clin Trials, 8, 56
- 1997, CenterWatch, 4, 1
- 10.1017/S0266462300009582 · DOI
- Rochon PA, 1998, CMAJ, 159, 1373
- 10.1001/archinte.154.2.157 · DOI
- 10.1001/jama.282.8.790 · DOI
- 10.1001/jama.277.15.1224 · DOI
- 10.1001/jama.263.10.1405 · DOI
- 10.1056/NEJM199808133390701 · DOI
- Phillips RA, 1998, CMAJ, 159, 955
- 10.1001/jama.277.15.1238 · DOI
- 10.1001/jama.277.4.297a · DOI
- 10.1016/S0140-6736(05)75272-7 · DOI
- 10.1016/S0140-6736(05)80075-3 · DOI
- 10.1001/jama.271.6.469 · DOI
- 10.1056/NEJM199409083311012 · DOI
- 10.1001/jama.280.3.222 · DOI · Paper page
- 10.1001/jama.277.11.927 · DOI
- 10.1056/NEJM199812173392512 · DOI
- Kunin CM, 1978, Ann Intern Med, 89, 842, 10.7326/0003-4819-89-5-842 · DOI
- 10.1001/jama.278.3.245 · DOI
- 10.1056/NEJM200005183422009 · DOI
Cited by
Sorted by citations
Items 301–400 of 641
Financial Conflicts of Interest in the School Psychology Assessment Literature.
Truscott, S. D., Baumgart, M., & Rogers, K. (2004) · School Psychology Quarterly · doi:10.1521/scpq.19.2.166.33311 · Cited by 11
Tobacco Industry Links to Faculties of Medicine in Canada
Kaufman, P., Cohen, J. E., Ashley, M., Ferrence, R., Halyk, A. L., Turcotte, F., Kyle, K., & Stewart, D. (2004) · Canadian journal of public health · doi:10.1007/bf03403650 · Cited by 11
Asthma in India: applying science to reality
Singh, R. (2004) · Clinical and Experimental Allergy · doi:10.1111/j.1365-2222.2004.1910.x · Cited by 11
Keinonen, T., Keränen, T., Klaukka, T., Saano, V., Ylitalo, P., & Enlund, H. (2003) · Pharmacy World & Science · doi:10.1023/b:phar.0000006517.36241.a5 · Cited by 11
Professional writing assistance: effects on biomedical publishing
Lagnado, M. (2003) · Learned Publishing · doi:10.1087/095315103320995050 · Cited by 8
Assessing faculty financial relationships with industry: a case study
Boyd, E., & Bero, L. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00842-x · Cited by 11
Clinical investigators and the pharmaceutical industry.
Newman, T. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430713 · Cited by 11
Surgical research publication in a selection of research and surgical specialty journals.
Donovan, A. J., & Tompkins, R. (2010) · Surgery · doi:10.1016/j.surg.2009.07.005 · Cited by 11
Moore, R., & Derry, S. (2018) · Pain Research and Management · doi:10.1155/2018/9493413 · Cited by 10
“While there may well be unease about industry-funded studies [55], for acute pain there is good evidence of no influence of industry funding on study results [56].”
BackgroundVariability in conflict of interest disclosures by physicians presenting trauma research
Wong, K., Yi, P., Mohan, R., & Choo, K. (2017) · World Journal of Orthopaedics · doi:10.5312/wjo.v8.i4.329 · Cited by 10
La investigación de la industria farmacéutica: ¿condicionada por los intereses del mercado?
Moreno, R. P. (2011) · Acta bioethica · doi:10.4067/s1726-569x2011000200010 · Cited by 12
“Bodenheimer T. Uneasy alliance – Clinical Investigators and the Pharmaceutical Industry.”
BackgroundInfluentialSummaries and recommendations of the global impression method
Trinh, K. (2009) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-009-0296-0 · Cited by 10
“not in the rating scales, such as funding source and past association, have been found to be important in introducing biases to the study, hence influencing the effect size of the study [ 15 ] . However, these factors might be difficult to quantify and were seldom included in the scales that were used in the past.”
Incremental Drug Treatment Cost in HIV-Positive Patients in Industry-Sponsored Clinical Trials
Perrín, R. S., & López, F. J. G. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l156 · Cited by 10
Roach, J., Skaggs, D., Sponseller, P., & Macleod, L. M. (2008) · Spine · doi:10.1097/brs.0b013e31817bd8f8 · Cited by 10
“supported 70% of the cost for clinical drug trials in the US.(2) The presence of a conflict of interest that might”
BackgroundInfluentialHow to ensure our readers' trust: the proper attribution of authors and contributors.
Liesegang, T., Albert, D., & Schachat, A. (2008) · American journal of ophthalmology-glaucoma · doi:10.1016/j.ajo.2008.06.007 · Cited by 10
Joussen, A., Lehmacher, W., Hilgers, R., & Kirchhof, B. (2007) · Survey of ophthalmology · doi:10.1016/j.survophthal.2007.02.010 · Cited by 10
Morss, R., & Hooke, W. (2005) · doi:10.1175/bams-86-7-921 · Cited by 10
“One technique for influencing results, sometimes used by pharmaceutical companies, is to retain control over studies ' designs, datasets, and analysis techniques—before, during, and after a study, and over the dissemination of results (Bodenheimer 2000; Schulman et al. 2002; Baird 2003; Bok 2003).”
BackgroundMethodEthical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis
Kavanaugh, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030817 · Cited by 10
“Other less blatant conflicts may arise from the financial compensation investigators receive for conducting studies. This may be of even greater concern with the trend towards greater numbers of clinical trials being performed in more diverse settings. In the USA in 1991, 80% of investigators in clinical studies were…”
Integrating Values in Risk Analysis of Biomedical Research: The Case for Regulatory and Law Reform
Waring, D. R., & Lemmens, T. (2004) · University of Toronto Law Journal · doi:10.1353/tlj.2004.0012 · Cited by 9
Budget Negotiation for Industry-Sponsored Clinical Trials
Beal, K., Dean, J., Chen, J. C., Dragaon, E., Saulino, A., & Collard, C. (2004) · Anesthesia and Analgesia · doi:10.1213/01.ane.0000122633.97424.76 · Cited by 10
“Industry-sponsored research thus represents the primary source of revenue for many clinical investigators ( 1 ,3).”
BackgroundInfluentialWeber, L., Wayland, M. T., & Holton, B. (2001) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2001.31006 · Cited by 10
Establishment of a clinical trials office at a children's hospital.
Abzug, M., & Esterl, E. A. (2001) · Pediatrics · doi:10.1542/peds.108.5.1129 · Cited by 10
Zhang, Y.-N., & Michelakis, E. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202103-0612ed · Cited by 9
“The biascreatedbythetendencytonotpublishnegative trialsbythe industry is well known (2, 5).”
BackgroundMorain, S. R., Joffe, S., Campbell, E., & Mello, M. M. (2015) · Journal of Law, Medicine & Ethics · doi:10.1111/jlme.12255 · Cited by 9
Lichter, A. S., McKinney, R. E., Anderson, T. D., Breese, E., Butler, D. L., Union, C., Campbell, E. G., Chimonas, S. C., Chisolm, G. M., Clark, C., et al. (2012) · NAM Perspectives · doi:10.31478/201211b · Cited by 8
“As data accumulate about the impact of nondisclosure of relationships, requirements are increasing for individual clinicians and researchers to report their relationships (Blumenthal, 1996; Bodenheimer, 2000; IOM, 2009).”
BackgroundAlfonso, F., Timmis, A., Pinto, F. J., Ambrosio, G., Ector, H., Kułakowski, P., Vardas, P. E., Loizos Antoniades, L., Ahmad, M., Apetrei, E., et al. (2012) · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) · doi:10.1016/j.repc.2011.12.014 · Cited by 2
Taekman, J. M., Stafford-Smith, M., Velazquez, E. J., Wright, M. C., Phillips-bute, B., Pfeffer, M., Sellers, M. A., Pieper, K. S., Newman, M., Werf, F. V. V. D., et al. (2010) · BMJ Quality & Safety · doi:10.1136/qshc.2008.028605 · Cited by 9
“[8] A significant portion of the $6 billion spent on clinical trials annually in the United States[11] is used for education to minimize errors.”
BackgroundBetter infrastructure: Industry–academia partnerships—A marriage of convenience?
Abraham, E. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181920725 · Cited by 6
Friedman, J. Y., Sugarman, J., Dhillon, J. K., Depuy, V., Pierre, C., Dinan, M., Allsbrook, J. S., Schulman, K., & Weinfurt, K. (2007) · Clinical Trials · doi:10.1177/1740774507079239 · Cited by 9
The benefits and threats of research partnerships with industry
Duval, G. (2005) · Critical Care · doi:10.1186/cc3539 · Cited by 9
“By 2002, 70% of funding for clinical trials came from industry [2].”
BackgroundTereskerz, P. M., & Moreno, J. D. (2005) · Accountability in Research · doi:10.1080/08989620590957229 · Cited by 9
“Most of these conflicts have been exhaustively described ( Bodenheimer, 2000 ; Kaplan and Browntee, 1999; Kuszler, 2001 ; Office of Inspector General, 2000 ; Tereskerz, 2003 ).”
BackgroundThe connection between academia and industry
Singh, A. R., & Singh, S. (2005) · Mens Sana monographs · doi:10.4103/0973-1229.27876 · Cited by 18
“Many of these drug trials are rigorously designed, employing the skills of outstanding clinical researchers at leading academic institutions (Bodenheimer, 2000).”
BackgroundInfluentialThe AbioCor artificial replacement heart: bioengineering meets bioethics.
Rothstein, M., & Anderlik, M. (2002) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/jcan.2002.31089 · Cited by 9
From clinical trial to prescription.
Carpenter, W. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.3.282 · Cited by 9
Sa, Y. (2000) · doi:10.1056/nejm200008173430712 · Cited by 9
Funding sources of practice-changing trials.
Dogan, S., Yamamoto-Ibusuki, M., & Andre, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx798 · Cited by 8
Authorship selection in industry‐sponsored publications of dermatology clinical trials
Tauber, M., & Paul, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15459 · Cited by 8
The Invention of an Investment Incentive for Pharmaceutical Innovation
Basheer, S. (2012) · The Journal of World Intellectual Property · doi:10.1111/jwip.12001 · Cited by 8
Professional ethics: an overview from health research ethics point of view.
Nyika, A. (2009) · Acta Tropica · doi:10.1016/j.actatropica.2009.07.033 · Cited by 8
Delawi, D., Dhert, W. J. A., & Öner, F. C. (2008) · European Spine Journal · doi:10.1007/s00586-008-0699-5 · Cited by 10
“Several articles addressed the essential role of independent research and expressed concerns about the increasing influence of industrial funding [1, 3, 9].”
BackgroundEthical issues in rheumatology clinical trials
Sugarman, J., & Bingham, C. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0829 · Cited by 8
“Clinical research is also now increasingly being conducted in physicians' practices, rather than in academic medical centers, where there might be less familiarity with conducting rigorous clinical research and oversight might be geographically distant from where the research is performed”
BackgroundThe pharmaceutical industry: friend or foe?
Niebyl, J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.11.055 · Cited by 8
van der Weyden, M. V. (2007) · Mens Sana Monographs · doi:10.4103/0973-1229.32145 · Cited by 8
“…be authors: whether members of the trial publication committee, employees of the sponsoring company or professional scientific writers; and whether to proceed or not with publication or what should be published (Friedman and Richter, 2004; Whittingham, et al., 2004; Giles, 2006; Bodenheimer, 2000).”
BackgroundInfluentialReport from the editorial office
Lameire, N., Floege, J., & Wheeler, D. (2005) · doi:10.1093/ndt/gfi349 · Cited by 8
Children and Psychotropic Medication: What Role Should Advocacy Counseling Play?
Ingersoll, R., Bauer, A. L., & Burns, L. (2004) · Journal of Counseling & Development · doi:10.1002/j.1556-6678.2004.tb00319.x · Cited by 9
“Bodenheimer (2000) has already raised the ethical implications of this uneasy alliance.”
BackgroundSetting biomedical research priorities in the 21st century.
Resnik, D. (2003) · The virtual mentor : VM · doi:10.1001/virtualmentor.2003.5.7.msoc1-0307 · Cited by 8
“Seventy percent of the clinical trials conducted in the US are industry-sponsored [4].”
BackgroundASSESSMENT OF NEW CARDIOVASCULAR DRUGS
Wieringa, N. F., Denig, P., de Graeff, P. A., & Vos, R. (2001) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462301107105 · Cited by 9
“Internists A (5) L (7) Cardiologists L (5), A (5) GPs A (4), L (5) Pharmacists A (4) L (4) Involvement in Yes A (8) L (8) guidelines No L (13) A (10) Expert Yes A (8), L (6) No L (15), A (10) Industry for Yes L (6) A (6) information No A (12), L (15) Adopter Early L (7) A (8) category Late A (10) L (14) Affiliation Ac…”
BackgroundSchetky, D. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2007.07.007 · Cited by 8
Ethical Issues Associated with Pharmaceutical Innovation
Eaton, M. L. (2007) · Springer eBooks · doi:10.1007/978-3-540-72310-3_4 · Cited by 4
“A related ethical question relates to a concern that corporate research protocol designs are manipulated or the data interpreted to achieve a result favorable to the commercialization of a drug ( Bodenheimer 2000 ).”
BackgroundConflicts of Interest and Strategic Ignorance of Harm
Dana, J. D. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511610332.016 · Cited by 11
Binko, M. A., Reitz, K. M., Chaer, R. A., Haga, L. M., Go, C. C., Alie-Cusson, F. S., Tzeng, E., Eslami, M. H., & Sridharan, N. D. (2023) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.05.035 · Cited by 8
Past, present and future of university hospitals
Raus, K., Mortier, E. P., & Eeckloo, K. (2019) · Acta Clinica Belgica · doi:10.1080/17843286.2019.1590024 · Cited by 13
“example, been raised about the independence of academic institutions [33] and in 2000 Marcia Angell provocatively asked whether academic medicine is for sale [34].”
BackgroundSeidler, A. L., Hunter, K. E., Chartres, N., & Askie, L. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222117 · Cited by 5
“For instance, in the United States 70% of money for drug trials is provided by industry.[1] The impact of industry involvement on study outcomes and how best to manage this has been widely debated in the scientific community.”
BackgroundGoswami, N. D., Tsalik, E. L., Naggie, S., Miller, W. C., Horton, J. R., Pfeiffer, C. D., & Hicks, C. B. (2014) · Trials · doi:10.1186/1745-6215-15-31 · Cited by 8
“In 2000, 70% of the clinical drug trial enterprise was funded by industry rather than by the National Institutes of Health (NIH), and as of 2010 this proportion is increasing [2,3].”
BackgroundRodríguez, E. L. R. (2011) · Acta bioethica · doi:10.4067/s1726-569x2011000100006 · Cited by 19
“Bodenheimer(17) denunció la creciente influencia de la industria farmacéutica sobre los ensayos clínicos.”
BackgroundManaging conflicts of interest and commitment: academic medicine and the physician's progress
Kachuck, N. (2010) · Journal of Medical Ethics · doi:10.1136/jme.2010.035832 · Cited by 7
Opinions of IRB Members and Chairs regarding Investigators' Relationships with Industry
Weissman, J., Koski, G., Vogeli, C., Thiessen, C., & Campbell, E. (2008) · Journal of Empirical Research on Human Research Ethics · doi:10.1525/jer.2008.3.1.3 · Cited by 7
“ACADEMIC-INDUSTRY RELATIONSHIPS (AIRS) in clinical research continue to receive much attention in academia and the media (Angell, 2000; Barnes & Florencio, 2003; Bodenheimer, 2000; Harris & Roberts, 2007; Kassirer, 2005; Krimsky, 2003; Leaf & Burke, 2005; Morin et al., 2002; Singer, 2007; Stolberg, 2000).”
BackgroundWho Should Sponsor Sleep Disorders Pharmaceutical Trials?
Kripke, D. F. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27020 · Cited by 8
Shane, E., Civitelli, R., Delmas, P., Drezner, M., Eisman, J., Lindsay, R., Lorenzo, J. A., Miller, P. D., Ralston, S., Reid, I., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07090c · Cited by 7
“Recent evidence indicates that investigators with ties to drug companies are more likely to report results favorable to those companies((2)) and that studies sponsored by industry are significantly more likely to report proindustry conclusions.”
BackgroundMethodAvaliação médica: o consumo na medicina e a mercantilização da saúde
dos Santos, J. C. M. (2006) · doi:10.1590/s0101-98802006000100011 · Cited by 7
Biomedicine and the human condition: challenges, risks, and rewards
Sargent, M. (2005) · Choice Reviews Online · doi:10.5860/choice.43-0356 · Cited by 4
Solyom, A. (2004) · Accountability in Research · doi:10.1080/03050620490512313 · Cited by 7
“Bodenheimer (2000) points out that the industry has gained additional control by setting up and sponsoring increasing number of clinical trials outside of university medical centers through Contract Research Organizations (CRO), Site Management Organizations (SMO) and forhire Institutional Review Boards (IRB). The shi…”
BackgroundInfluentialFunding and Practice of Biomedical Research
Staropoli, J. (2003) · doi:10.1001/jama.290.1.112 · Cited by 7
Ippoliti, R. (2013) · Value in Health · doi:10.1016/j.jval.2012.09.010 · Cited by 11
“Indeed, as suggested by Bodenheimer [17], each day’s delay in gaining Food and Drug Administration approval of a drug, the manufacturer loses, on average, $1.”
MethodBiomedical Research and Mining of the Poor: The Need for Their Exclusion
Rr, K. (2006) · doi:10.1007/s11948-006-0017-8 · Cited by 7
The public-private research ecosystem in the genome editing era
Major, R. M., Davis, A. M., Henderson, G. E., Inamine, G., & Conley, J. M. (2024) · iScience · doi:10.1016/j.isci.2024.109896 · Cited by 6
Saini, G., Gogineni, K., Kittles, R. A., & Aneja, R. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06264-x · Cited by 8
Transparency in clinical trial reporting
Rochon, P. A., Stall, N. M., Savage, R., & Chan, A. (2018) · BMJ · doi:10.1136/bmj.k4224 · Cited by 8
Conflict of interests in initial clinical practice involving patients whith lung neoplasia
Santos, M., da Silva, D. A. C., & Paranhos, F. (2014) · Revista Bioética · doi:10.1590/1983-80422014223033 · Cited by 6
Publication and reporting biases and how they impact publication of research
Rodrigues, V. (2019) · Editage Insights · doi:10.34193/ei-a-6299 · Cited by 3
Turning Endogenous Peptides into New Analgesics: The Example of Kyotorphin Derivatives
Ribeiro, M. M. B., Serrano, I., & Santos, S. S. (2011) · doi:10.1002/9783527636730.ch8 · Cited by 6
Hess, J. Z., & Lacasse, J. (2011) · Families in Society The Journal of Contemporary Social Services · doi:10.1606/1044-3894.4138 · Cited by 6
“, Sismondo, 2008), articles in major medical journals have issued warnings regarding the prevalence of industry-funded research efforts and the “uneasy alliance” they entail with the helping professions (Bodenheimer, 2000; Campbell et al., 2007).”
BackgroundTo ban or not to ban: direct-to-consumer advertising and human rights analysis
Wellington, A. (2012) · Edward Elgar Publishing eBooks · doi:10.4337/9781781005774.00017 · Cited by 3
Dangerous Liaisons? Industry Relations with Health Professionals
Sade, R. M. (2009) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2009.00400.x · Cited by 6
International research and just sharing of benefits in Mexico.
Paez, R., & de Alba, J. D. (2009) · Developing World Bioethics · doi:10.1111/j.1471-8847.2008.00228.x · Cited by 6
‘We Have to Go Where the Money Is’—Dilemmas in the Role of Nutrition Scientists: An Interview Study
Folker, A. P., Holm, L., & Sandøe, P. (2009) · Minerva · doi:10.1007/s11024-009-9122-6 · Cited by 6
„Health Technology Assessment“
Wild, C. (2006) · Der Anaesthesist · doi:10.1007/s00101-006-0999-2 · Cited by 6
The Challenge of Infectious Diseases to the Biomedical Paradigm
Foladori, G. (2005) · doi:10.1177/0270467604274337 · Cited by 6
Rosenzweig, M., Bender, C., & Brufsky, A. (2005) · Oncology Nursing Forum · doi:10.1188/05.onf.293-299 · Cited by 6
“One large teaching hospital found that 30%–50% of all research contracts had to be renegotiated because of an unacceptable publishing clause (Bodenheimer, 2000).”
BackgroundBalancing commercial and public interests
Furberg, C., Hall, M., & Sevick, M. (2004) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-5-6 · Cited by 6
“At times, manufacturers exert undue pressure on investigators to give trial results a more positive "spin" [6,7].”
Hidden Truths: The Politics of Brain, Mind and Soul in Australian Psychiatry
Halasz, G. (2004) · Australasian Psychiatry · doi:10.1046/j.1039-8562.2003.02051.x · Cited by 6
Financial associations of authors.
Relman, A. (2002) · New England Journal of Medicine · doi:10.1056/nejm200209263471320 · Cited by 6
Conflict of interest as seen from a researcher’s perspective
Schieppati, A., Perico, N., & Remuzzi, G. (2002) · Science and Engineering Ethics · doi:10.1007/s11948-002-0053-y · Cited by 6
Kuthiala, S., Lyman, G., & Ballester, O. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705230 · Cited by 6
Achieving Large-Scale Change in Medical Education
Curry, L. (2002) · Springer international handbooks of education · doi:10.1007/978-94-010-0462-6_39 · Cited by 6
Wettstein, M., Pazhepurackel, C., Neumann, A., Woon, D., Herrera-Caceres, J., Kozomara, M., Poyet, C., Sulser, T., Kulkarni, G., & Hermanns, T. (2019) · World journal of urology · doi:10.1007/s00345-019-02799-3 · Cited by 5
Evidence-based medicine from a social science perspective
Stevens, H. (2018) · Australian Journal of General Practice · doi:10.31128/ajgp-03-18-4528 · Cited by 5
Tibau, A., Anguera, G., Pretel, F. A., Templeton, A. J., Šeruga, B., Barnadas, A., Amir, E., & Ocaña, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24589 · Cited by 4
“Although the pharmaceutical industry plays a key role in the discovery of novel drugs, the collaboration with physicians in academic institutions is essential during clinical evaluation [2].”
BackgroundKong, N. H. Y., & Chow, P. K. H. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.03.012 · Cited by 4
Alfonso, F., Timmis, A., Pinto, F. J., Ambrosio, G., Ector, H., Kułakowski, P., Vardas, P. E., Antoniades, L., Ahmad, M., Apetrei, E., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.02.002 · Cited by 7
Rubin, E. B., & Bernat, J. (2008) · Headache · doi:10.1111/j.1526-4610.2008.01307.x · Cited by 5
Farmacêutico: profissional de saúde e cidadão
Rozenfeld, S. (2008) · doi:10.1590/s1413-81232008000700002 · Cited by 5
Duval, G. (2004) · Journal of Law, Medicine & Ethics · doi:10.1111/j.1748-720x.2004.tb01967.x · Cited by 5
The commercialization of clinical research: who pays the piper, calls the tune?
Freemantle, N., & Stocken, D. D. (2004) · Family Practice · doi:10.1093/fampra/cmh425 · Cited by 5
Helft, P., Ratain, M., Epstein, R., & Siegler, M. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh121 · Cited by 5
Clinical Research and Industrial Sponsoring: Avenues towards Transparency and Credibility
Hildebrandt, M., & Ludwig, W.-D. (2003) · Oncology Research and Treatment · doi:10.1159/000074146 · Cited by 5
Integrity and bias in academic psychiatry
Bola, J. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.183.5.464 · Cited by 5
Conflict of interest and medical publication
Reidenberg, M. (2002) · Science and Engineering Ethics · doi:10.1007/s11948-002-0067-5 · Cited by 5
Scientific Data from Clinical Trials: Investigators’ Responsibilities and Rights
Polk, H., Bowden, T., Rikkers, L., Balch, C., Organ, C., Murie, J., Pories, W., Buechler, M., Neoptolemos, J., Fazio, V., et al. (2002) · Journal of Pediatric Surgery · doi:10.1001/archsurg.137.6.639 · Cited by 5
Metadata
- Authors
- Bodenheimer, T.
- Corresponding author
- Bodenheimer, Thomas
- ORCID
- Bodenheimer, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-05-18
- Volume
- 342
- Issue
- 20
- Pages
- 1539-1544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2337821671
- Cited by
- 765
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 17 · 2019: 11 · 2018: 14 · 2017: 18 · 2016: 11 · 2015: 14 · 2014: 20 · 2013: 31 · 2012: 34
- FWCI
- 51.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- clinical investigators, pharmaceutical industry, contract research organizations, academic medical centers, clinical trials, conflicts of interest, drug development
- MeSH terms
- Academic Medical Centers, Authorship, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Interinstitutional Relations, Publishing, Research Support as Topic, Social Change, United States, United States Food and Drug Administration, Conflict of Interest, Drug Approval, Disclosure, Contracts, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
